Trends of Plasmodium falciparum molecular markers associated with resistance to artemisinins and reduced susceptibility to lumefantrine in Mainland Tanzania from 2016 to 2021

Catherine Bakari,Celine I. Mandara,Rashid A. Madebe,Misago D. Seth,Billy Ngasala,Erasmus Kamugisha,Maimuna Ahmed,Filbert Francis,Samwel Bushukatale,Mercy Chiduo,Twilumba Makene,Abdunoor M. Kabanywanyi,Muhidin K. Mahende,Reginald A. Kavishe,Florida Muro,Sigsbert Mkude,Renata Mandike,Fabrizio Molteni,Frank Chacky,Dunstan R. Bishanga,Ritha J. A. Njau,Marian Warsame,Bilali Kabula,Ssanyu S. Nyinondi,Naomi W. Lucchi,Eldin Talundzic,Meera Venkatesan,Leah F. Moriarty,Naomi Serbantez,Chonge Kitojo,Erik J. Reaves,Eric S. Halsey,Ally Mohamed,Venkatachalam Udhayakumar,Deus S. Ishengoma
DOI: https://doi.org/10.1186/s12936-024-04896-0
2024-03-12
Malaria Journal
Abstract:Therapeutic efficacy studies (TESs) and detection of molecular markers of drug resistance are recommended by the World Health Organization (WHO) to monitor the efficacy of artemisinin-based combination therapy (ACT). This study assessed the trends of molecular markers of artemisinin resistance and/or reduced susceptibility to lumefantrine using samples collected in TES conducted in Mainland Tanzania from 2016 to 2021.
infectious diseases,tropical medicine,parasitology
What problem does this paper attempt to address?